Pamela Haylock on the Role of CSTDs
Pamela Haylock, PhD, RN, FAAN, past president, Oncology Nursing Society, discusses the role of closed-system drug-transfer devices (CSTDs).
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
Ruxolitinib Cream Improves Body Surface Area in Cutaneous GVHD
2 Commerce Drive Cranbury, NJ 08512